Estimation of treatment effect in clinical trials of continuous endpoints with retrieved dropouts
含停药后恢复随访者的连续终点临床试验处理效应估计AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
本页为预印本版本;arXiv 收录、作者填写的期刊信息以及作者既有发表经历,都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对,只展示已核实例,档案仍可能误合并。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要明确研究临床试验处理效应及不同伴发事件策略下的目标量估计,直接对应因果推断。
含停药后恢复随访者的连续终点临床试验处理效应估计AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
The estimand framework provides guidance on handling intercurrent events, such as treatment discontinuation, in the analysis of clinical trial responses. Under ICH E9(R1), the treatment policy (TP) strategy incorporates post-discontinuation data to reflect treatment effects in real-world practice. However, many existing approaches focus primarily on imputing missing endpoint values for lost-to-follow-up subjects and do not explicitly model completers, retrieved dropouts (RDs), and lost-to-follow-up subjects within a unified framework. This may obscure the relationship between modeling assumptions and the estimand of interest when RD data are present. We propose a likelihood-based model for continuous endpoints that integrates data from all subject categories, including RDs. The approach combines an analysis of covariance formulation with a probit model for treatment discontinuation, enabling explicit formulation of treatment effects for estimands defined using the hypothetical and TP strategies. Estimation is carried out via a computationally efficient maximum likelihood procedure. Numerical studies demonstrate that the proposed method achieves improved bias and variability properties compared with commonly used imputation-based approaches.